Antilipidemic Drugs

Correct Answer

B — Statins

Rationale

Statins are classified as competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Bile acid sequestrants act by binding bile acids in the intestinal lumen. proprotein convertase subtilisin/kexin type 9 inhibitors are monoclonal antibodies or small interfering ribonucleic acid agents targeting proprotein convertase subtilisin/kexin type 9. Fibrates are a drug class used primarily for triglyceride reduction.

Correct Answer

D — Ezetimibe

Rationale

Ezetimibe is classified as an inhibitor of the Niemann-Pick C1-Like 1 transporter, the protein responsible for cholesterol absorption across the intestinal brush border. Evolocumab is a monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitor. Inclisiran is a small interfering ribonucleic acid proprotein convertase subtilisin/kexin type 9 inhibitor. Atorvastatin is a statin, classified as an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Correct Answer

A — Inclisiran

Rationale

Inclisiran is classified as a small interfering ribonucleic acid agent. It is the only drug in this list that belongs to the ribonucleic acid interference drug class. Evolocumab and alirocumab are both monoclonal antibodies. Ezetimibe is a Niemann-Pick C1-Like 1 transporter inhibitor.

Correct Answer

C — Evolocumab and alirocumab

Rationale

Evolocumab and alirocumab are both classified as monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors. Inclisiran is also a proprotein convertase subtilisin/kexin type 9 inhibitor but belongs to a different drug class — it is a small interfering ribonucleic acid agent, not a monoclonal antibody. Ezetimibe is a Niemann-Pick C1-Like 1 transporter inhibitor and is not a proprotein convertase subtilisin/kexin type 9 inhibitor.

Correct Answer

B — Bile acid sequestrants

Rationale

Cholestyramine, colestipol, and colesevelam are all classified as bile acid sequestrants. Fibrates are a separate drug class used primarily for triglyceride reduction. proprotein convertase subtilisin/kexin type 9 inhibitors are monoclonal antibodies or small interfering ribonucleic acid agents targeting proprotein convertase subtilisin/kexin type 9. Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Correct Answer

D — Fenofibrate

Rationale

Fenofibrate is classified as a fibrate, a drug class used primarily for triglyceride reduction. Ezetimibe is a Niemann-Pick C1-Like 1 transporter inhibitor. Rosuvastatin is a statin, classified as an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Colesevelam is a bile acid sequestrant.

Correct Answer

A — Inhibition of hepatic cholesterol synthesis reduces intracellular cholesterol, triggering compensatory upregulation of low-density lipoprotein receptors on the hepatocyte surface

Rationale

Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. The resulting fall in intracellular hepatocyte cholesterol triggers compensatory upregulation of low-density lipoprotein receptor expression on the hepatocyte surface. More receptors clear more low-density lipoprotein particles from the plasma — this is the primary mechanism of low-density lipoprotein cholesterol reduction. Statins do not bind low-density lipoprotein directly, do not inhibit intestinal absorption (that is ezetimibe), and do not activate lipoprotein lipase (that is a fibrate-related effect on triglyceride-rich particles).

Correct Answer

C — Statin therapy upregulates proprotein convertase subtilisin/kexin type 9, which directs low-density lipoprotein receptors toward lysosomal degradation rather than recycling

Rationale

Statin therapy reduces intracellular hepatic cholesterol and triggers compensatory upregulation of low-density lipoprotein receptors. However, statins also increase proprotein convertase subtilisin/kexin type 9 expression as a counterregulatory response. Proprotein convertase subtilisin/kexin type 9 binds low-density lipoprotein receptors on the hepatocyte surface and escorts them to lysosomal degradation rather than allowing them to recycle back to the surface. This partially offsets the receptor upregulation statins otherwise produce — and is precisely why blocking proprotein convertase subtilisin/kexin type 9 amplifies the low-density lipoprotein lowering effect of statins dramatically. Statins do not suppress low-density lipoprotein receptor transcription or increase intestinal absorption.

Correct Answer

B — Ezetimibe reduces intestinal cholesterol delivery to the liver, depleting hepatic cholesterol through a complementary route and producing additional low-density lipoprotein receptor upregulation

Rationale

Ezetimibe blocks the Niemann-Pick C1-Like 1 transporter in the intestinal brush border, reducing cholesterol absorption. Less cholesterol reaching the liver depletes hepatic intracellular cholesterol, which activates the same sterol regulatory element-binding protein 2 pathway that statins activate — driving additional low-density lipoprotein receptor upregulation and increased plasma low-density lipoprotein clearance. Because the two drugs deplete hepatic cholesterol by different routes, their effects on receptor upregulation are additive. Ezetimibe does not inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase, does not block proprotein convertase subtilisin/kexin type 9, and does not directly affect biliary cholesterol excretion.

Correct Answer

D — It prevents proprotein convertase subtilisin/kexin type 9 from escorting low-density lipoprotein receptors to lysosomal degradation, allowing more receptors to recycle to the hepatocyte surface

Rationale

Proprotein convertase subtilisin/kexin type 9 is a serine protease secreted by the liver that binds low-density lipoprotein receptors on the hepatocyte surface and directs them to lysosomal degradation rather than recycling. Evolocumab is a monoclonal antibody that blocks proprotein convertase subtilisin/kexin type 9, preventing this degradation and allowing receptors to recycle back to the surface. The resulting increase in receptor density dramatically amplifies low-density lipoprotein clearance from the plasma. The other mechanisms listed describe statins (option B) and ezetimibe (option C), not monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors. Evolocumab does not directly activate sterol regulatory element-binding protein 2.

Correct Answer

B — They bind bile acids in the intestinal lumen, interrupting enterohepatic recirculation and forcing the liver to convert more cholesterol to bile acids, which depletes hepatic cholesterol and upregulates low-density lipoprotein receptors

Rationale

Bile acid sequestrants bind bile acids in the intestinal lumen and prevent their reabsorption, interrupting the enterohepatic recirculation that normally returns bile acids to the liver. The liver must then convert more of its intracellular cholesterol into new bile acids to replenish the lost pool. This depletion of hepatic cholesterol triggers upregulation of low-density lipoprotein receptor expression on the hepatocyte surface, increasing plasma low-density lipoprotein clearance. The mechanisms in options A, C, and D describe statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors respectively — none of which are the mechanism of bile acid sequestrants.

Correct Answer

C — Scavenger receptor class B type I, which selectively takes up cholesterol from high-density lipoprotein at the hepatocyte surface

Rationale

Scavenger receptor class B type I is the hepatic receptor responsible for selective uptake of cholesterol from high-density lipoprotein particles, completing reverse cholesterol transport. Unlike the low-density lipoprotein receptor, which internalizes entire particles, scavenger receptor class B type I selectively extracts cholesterol from high-density lipoprotein while returning the lipid-depleted particle to the circulation. The low-density lipoprotein receptor binds apolipoprotein B-100 and is the receptor for low-density lipoprotein, not high-density lipoprotein. High-density lipoprotein carries apolipoprotein A-I, not apolipoprotein B-100 or apolipoprotein E as its primary receptor ligand for hepatic uptake.

Correct Answer

A — Thyroid hormone deficiency reduces hepatic low-density lipoprotein receptor expression, impairing clearance of low-density lipoprotein from the plasma

Rationale

Thyroid hormone normally promotes the expression of low-density lipoprotein receptors on hepatocytes. When thyroid hormone levels fall in hypothyroidism, receptor expression decreases, less low-density lipoprotein is cleared from the plasma, and low-density lipoprotein cholesterol accumulates. This is why thyroid-stimulating hormone should be checked in any patient with unexplained hypercholesterolemia before initiating statin therapy — correcting the hypothyroidism alone may normalize or substantially improve the lipid panel. Reduced lipoprotein lipase activity in hypothyroidism primarily affects triglyceride clearance rather than low-density lipoprotein cholesterol. Thyroid hormone deficiency does not directly upregulate proprotein convertase subtilisin/kexin type 9.

Correct Answer

D — Acute pancreatitis due to the accumulation of triglyceride-rich chylomicron remnants in the pancreatic microcirculation

Rationale

At triglyceride levels above 500 milligrams per deciliter — and especially above 1,000 milligrams per deciliter — the accumulation of triglyceride-rich particles in the pancreatic microcirculation can cause acute pancreatitis, a potentially life-threatening emergency. This risk is distinct from the atherosclerotic cardiovascular risk associated with moderate triglyceride elevations and requires specific treatment aimed at triglyceride reduction, including very-low-fat diet and triglyceride-targeted drugs such as fibrates or omega-3 fatty acids. Hepatic failure, acute kidney injury, and rhabdomyolysis are not recognized consequences of severe hypertriglyceridemia in the absence of other causes.

Correct Answer

C — Ezetimibe reduces intestinal cholesterol absorption, depleting hepatic cholesterol through a complementary route and producing additional low-density lipoprotein receptor upregulation beyond what the statin alone achieves

Rationale

Ezetimibe blocks the Niemann-Pick C1-Like 1 transporter in the intestinal brush border, reducing cholesterol absorption. Less cholesterol reaching the liver depletes hepatic intracellular cholesterol, activating the sterol regulatory element-binding protein 2 pathway and driving additional low-density lipoprotein receptor upregulation — the same pathway the statin activates, but through a different input. Because the two drugs reduce hepatic cholesterol by different routes, their receptor upregulation effects are additive, explaining the further low-density lipoprotein cholesterol reduction seen with combination therapy. Ezetimibe does not inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase or block proprotein convertase subtilisin/kexin type 9.

Correct Answer

A — Statins act by upregulating hepatic low-density lipoprotein receptors to clear low-density lipoprotein from the plasma; they do not restore the lipoprotein lipase activity required to hydrolyze triglycerides from chylomicrons at the capillary wall

Rationale

Statins reduce plasma low-density lipoprotein cholesterol by inhibiting hepatic cholesterol synthesis, which triggers compensatory low-density lipoprotein receptor upregulation and increased low-density lipoprotein clearance. This mechanism has no bearing on the hydrolysis of chylomicron triglycerides, which depends entirely on lipoprotein lipase at the capillary wall. In familial chylomicronemia syndrome, lipoprotein lipase is absent or nonfunctional, so chylomicrons and their triglycerides cannot be cleared regardless of statin dose. Treatment must target triglyceride production or chylomicron assembly through dietary fat restriction and triglyceride-specific agents. Statins are not rapidly metabolized specifically in this condition, do not inhibit chylomicron assembly, and do not require functional lipoprotein lipase to act.

Correct Answer

B — Restored thyroid hormone levels increase hepatic low-density lipoprotein receptor expression, enhancing clearance of low-density lipoprotein from the plasma

Rationale

Thyroid hormone promotes the expression of low-density lipoprotein receptors on hepatocytes. In hypothyroidism, thyroid hormone deficiency reduces receptor expression, impairing low-density lipoprotein clearance and causing low-density lipoprotein cholesterol to accumulate. When levothyroxine restores thyroid hormone levels, low-density lipoprotein receptor expression is also restored, and plasma low-density lipoprotein cholesterol falls — often substantially — without any lipid-specific drug. This is why thyroid-stimulating hormone should be measured before initiating statin therapy in any patient with unexplained hypercholesterolemia. Levothyroxine does not directly inhibit very low-density lipoprotein secretion, activate peroxisome proliferator-activated receptor alpha, or alter Niemann-Pick C1-Like 1 transporter expression.

Correct Answer

D — proprotein convertase subtilisin/kexin type 9 inhibitors

Rationale

Proprotein convertase subtilisin/kexin type 9 inhibitors reduce lipoprotein(a) levels by approximately 20 percent as an effect beyond their primary low-density lipoprotein cholesterol lowering. Lipoprotein(a) levels are more than 90 percent genetically determined and are not meaningfully reduced by statins, ezetimibe, bile acid sequestrants, or fibrates. Among currently available standard lipid-lowering drugs, only proprotein convertase subtilisin/kexin type 9 inhibitors produce a clinically meaningful reduction in lipoprotein(a), which is why they are of particular interest in high-risk patients with elevated lipoprotein(a). Novel agents specifically targeting lipoprotein(a) synthesis — such as small interfering ribonucleic acid and antisense oligonucleotide agents — are in late-stage clinical development and are expected to achieve much larger reductions.